

INTRODUCTION AND AIM OF WORK

REVIEW
OF
LITERATURE

SUMMARY

REFERENCES

*ARABIC
SUMMARY*

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

قَالُوا سُبْحَانَكَ

لَا عِلْمَ لَنَا إِلَّا مَا عَلَّمْتَنَا

إِنَّكَ أَنْتَ الْعَلِيمُ الْحَكِيمُ

صَدَقَ اللَّهُ الْعَظِيمُ

NON-HORMONAL TREATMENT FOR MENOPAUSE

THESIS

**Submitted for Partial Fulfillment of Masters Degree in
Obstetrics & Gynecology**

BY

Mohamed Ibrahim Mohamed Ibrahim Magdi
M.B., B.Ch., Cairo University

SUPERVISORS

Prof. Dr. AHMED LOTFY EL-DALI

Prof. of Obstetrics & Gynecology
Faculty of Medicine
Cairo University

Prof. Dr. REDA ISMAIL REYAD

Prof. of Obstetrics & Gynecology
Faculty of Medicine
Cairo University

**Faculty of Medicine
Cairo University
2006**

To The Memory of My Mother

Who inspired me throughout my life

To My Father

For his love and support

To My Family

***For their patience and generous support
through this work***

Acknowledgement

*I wish to express my supreme and deep gratitude to **Professor Dr. AHMED EL-DALI**, Professor of Obstetrics & Gynecology, Faculty of Medicine, Cairo University, for his expert advise, generous assistance and valuable guidance throughout this work..*

*I am deeply grateful and sincerely thankful to **Professor Dr. REDA ISMAIL**, Professor of Obstetrics & Gynecology, Faculty of Medicine, Cairo University, for his effort and encouragement throughout the work. He was generous with time, effort and support. His remarks were the backbone for the work.*

M. Ibrahim Magdi

2006

LIST OF CONTENTS

INTRODUCTION.....	1
AIM OF WORK.....	3
REVIEW OF LITERATURE.....	
▪ Menopause.....	4
<i>Epidemiology.....</i>	4
<i>Perimenopausal phases.....</i>	5
<i>Hormonal changes.....</i>	7
<i>Menopause, a women's concern.....</i>	9
<i>Diagnosis of hormonal changes.....</i>	12
<i>Symptoms.....</i>	14
▪ Contraindication to hormone therapy.....	30
▪ Hormonal versus non-hormonal treatment—An Evaluation.....	31
▪ Non-hormonal management of post-menopausal effects.....	50
SUMMARY.....	135
REFERENCES.....	
ARABIC SUMMARY.....	141

List Of abbreviations

ACE	Angiotensin-converting enzyme
ACOG	American College of Obstetricians and Gynecologists
AFCAPS/TexCAPS	Air Force/Texas Coronary Atherosclerosis Prevention Study
ApoA1	Apolipoprotein A1
ApoB	Apolipoprotein B
ARBs	Angiotensin-receptor blockers
ARR	Absolute risk reduction
BRCA-1 gene	Breast cancer gene
BMD	Bone mineral density
BMI	Body mass index
CAD	Coronary artery disease
CARE	Cholesterol and Recurrent Events
CEE	Conjugated equine estrogen
CHD	Coronary heart disease
CI	Confidence interval
COLIA1	Collagen I alpha 1
CR	Controlled-release
CSMH	Committee on Safety of Human Medicines
CVD	Cardiovascular disease
DEXA	Dual Energy X-ray Absorptiometry
DXA	Dual X-ray Absorptiometry
GABA	G-aminobutyric acid
GI	Generalizable index
GTF	Glucose tolerance factor
p DXA	Peripheral dual X-ray Absorptiometry
Dpd	Deoxypyridinoline
E1	Estrone
E2	Estradiol
EFAs	Essential fatty acids
EPT	Estrogen-progestogen therapy
ER	Estrogen receptor
ERT	Estrogen replacement therapy
ESPRIT	Estrogen therapy for prevention of reinfarction in postmenopausal women team
FDA	Food and drug administration
FIT	Fracture Intervention Trial
FSH	Follicle-stimulating hormone

HDL	High-density lipoprotein
HDL-C	High-density lipoprotein cholesterol
HERS	The Heart and Estrogen/Progestin Replacement Study
HIP	Hip Intervention Program
HRT	Hormone replacement therapy
HT	Hormone therapy
5-HT receptor	5-hydroxy tryptamine receptor
INR	International normalized ratio
LDL	Low- density lipoprotein
LDL-C	low-density lipoprotein cholesterol
LH	Luteinizing hormone
LH-RH	Luteinizing hormone releasing hormone
Lp(a)	Lipoprotein(a)
MI	Mitral incompetence
MORE	Multiple Outcomes of Raloxifene Evaluation
MPA	Medroxyprogesterone acetate
NIH	National Institutes of Health
NNH	Number needed to harm
NNT	Number needed to treat
pDEXA	Peripheral Dual Energy X-ray Absoptiometry
PEPI	Postmenopausal Estrogen/Progestin Interventions Study.
PROOF	Prevent Recurrence of Osteoporotic Fractures
PTH	Parathyroid hormone
QCT	Quantitative computed tomography
RCT	Randomized controlled trial
RDA	Recommended daily allowance
SERMs	Selective estrogen receptor modulators
SD	Standard deviation
SORT	Strength of recommendations table
SOTI	Spinal Osteoporosis Therapeutic Intervention
SSRI	Selective serotonin reuptake inhibitor
STEAR	Selective Tissue Estrogenic Activity Regulator
SXA	Single X-ray Absoptiometry
TC	Total cholesterol
TG	Triglyceride
TROPOS	TReatment Of Peripheral OSteoporosis
VD	Vitamin D receptor gene
VERT	Vertebral Efficacy with Risedronate Therapy
WHI	Women's Health Initiative
WHIM	Women's Health Initiative Memory Study
XR	Extended-release

